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Extending beyond genomic explorations that have successfully identified proatherosclerotic pathways such as LPA and PCSK9, several landmark papers this year reported on the identification of novel and rare genetic variants that highlight the involvement of additional processes in lipid metabolism which influence atherosclerotic risk (FIG. 1 ). Nioi and colleagues described genetic determinants that contribute to variations in the level of atherogenic lipoproteins 1 . Apolipoprotein B-containing particles can be captured globally by measuring non-HDL cholesterol (non-HDLc; calculated by deducting HDL cholesterol from total choles terol). Non-HDLc is superior to LDL cholesterol in predicting coronary artery disease (CAD) risk, and the year 2016 marked the important discovery of a genetic associ ation between variants affecting nonHDLc and CAD risk, and the protein asialoglycoprotein receptor 1 (ASGR1) 1 . ASGR1 is a lectin sub unit of the transmembrane protein asialoglyco protein receptor that has a critical role in serum glycoprotein homeostasis. In genetic discovery studies that initially involved approximately 400,000 Icelandic individuals, which were then validated in case-control studies from five European ancestry cohorts of approximately 300,000 individuals, carriers (approximately 1 in 120 Icelandic individ uals) of a noncoding 12-basepair deletion in intron 4 of ASGR1 were found to have reduced non-HDLc levels, and an accompanying marked reduction in risk of CAD 1 . Carriers of this loss-of-function genetic variant had a mean 15 mg/dl reduction in non-HDLc, a ~34% reduction in myocardial infarction risk, Hypertriglyceridaemia is another wellestablished cardiovascular risk factor. The important role of angiopoietin-related protein 4 (ANGPTL4) in modulating triglyceride levels by inhibiting lipoprotein lipase (LPL), and in reducing the risk of CAD were validated in two separate large-scale genomic analyses in 2016 (REFS 2,3). Carriers of loss-of-function variants of SVEP1 (p.D2702G) and ANGPTL4 (p.E40K) had lower triglyceride levels than noncarriers; these mutations were also associated with protection from CAD 2 . Furthermore, a loss-of-function variant mutation in LPL (p.D36N) was associated with increased CAD risk, whereas a gain-of-function variant (p.S447*) was associated with reduced risk of CAD 2 . In an independent investigation reported this year, carriers of the E40K variant and 13 other monoallelic inactivating mutation variants of ANGPTL4 all had lower triglyceride levels and higher HDLc levels than noncarriers, and were less likely to have CAD 3 . In addition, monoclonal antibody inhib ition of the ANGPTL4 protein in both mouse and nonhuman primate models resulted in a reduction in triglyceride levels 3 . and a lifespan prolonged by 1.5 years compared with noncarriers 1 . The mechanisms under lying the pronounced athero protective effects of this variant, however, are unclear. This study thus reported that loss-of-function mutations in ASGR1 result in non-HDLc reductions and marked protection from CAD, and identify ASGR1 as a potential therapeutic target for the treatment and/or prevention of CAD 1 .
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Advances in new therapeutic targets for atherosclerosis
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In 2016, advances in atherosclerosis research were focused on the discovery and validation of new targets with genetic and mechanistic links to atherothrombotic heart disease. Novel targets include proteins involved in glycoprotein recognition and clearance, regulators of triglyceride-rich particle metabolism, inflammatory pathways that impair efferocytosis, and the gut microbiome. Nature Reviews | Cardiology , and defective efferocytosis (CD47), which are linked to coronary artery disease. Gut microorganism-associated metabolism of dietary nutrients that are abundant in Western diets lead to the generation of the metabolite trimethylamine N-oxide (TMAO) , which is associated with enhanced coronary atherosclerotic plaque burden, heightened platelet responsiveness, and thrombotic complications. Therapeutic interventions with antibodies against PCSK9 in humans reduce LDL-cholesterol levels, inhibit coronary atherosclerosis progression, and promote plaque regression, whereas anti-CD47 therapy in animal models provides proof-of-concept validation for inhibition of atherosclerosis. mAB, monoclonal antibodies.
Despite the strong inverse association between HDLc and CAD risk, results from therapeutic intervention trials targeting HDLc levels have yielded frustratingly negative findings. Perhaps some of the confusion surrounding HDLc was clarified through genomic analyses published this year of rare variants in individuals with high HDLc. Mice with a Scarb1 knockdown have markedly elevated HDLc levels and paradoxically increased risk of atherosclerosis 4 . Targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with high plasma HDLc levels led to the identification of a homozygote mutation for a loss-of-function variant (P376L) in SCARB1 that impairs post-translational processing of the scavenger receptor class B member 1 protein and abrogates selective HDLc uptake in transfected cells 4 . Carriers of this SCARB1 variant showed paradoxically elevated HDLc and an increased risk of CAD.
Progress has also been made this year in interventional studies for the treatment of atherosclerosis. Findings from the GLAGOV study 5 suggest that PCSK9 inhibition might reverse coronary atherosclerosis via incremental LDL-cholesterol lowering, even in the presence of aggressive statin therapy. Statintreated patients (n = 938) with angiographic CAD were prospectively randomly assigned to subcutaneous evolocumab (a PCSK9 inhibitor) or placebo for 76 weeks and assessed by serial intravascular coronary ultrasono graphy 5 . Compared with placebo, the evolocumab group had lower LDL-cholesterol levels (as low as 20 mg/dl), had a greater decrease in atheroma volume, and showed plaque regression in a greater proportion of patients, without serious adverse effects. Although the study was not powered to assess clinical outcomes, major adverse cardiac events were numerically reduced with evolocumab therapy. These findings suggest that PCSK9 inhibition in the setting of intensive statin therapy can influence plaque progression and foster reversal of atherosclerosis.
Further mechanistic links between inflammation and atherosclerosis have also been explored 6 . Advanced lesions at risk of rupture are characterized by accumulation of diseased vascular cells and apoptotic cellular debris; why these cells are not cleared within atheroma remains unknown. Upregulation of CD47, an antiphagocytic molecule (a 'don't eat me' signal) known to render malignant cells resistant to programmed cell removal (efferocytosis), occurs during atherogenesis (FIG. 1) . Impaired efferocytosis might have a pathogenic role in cardiovascular disease. In a 2016 study, CD47 was upregulated in both human coronary and carotid atheros clerotic vessels, presum ably via a tumour necrosis factor (TNF)-α and NFκB1-dependent process that results in inhibition of efferocytosis 6 . Moreover, administration of CD47-blocking antibodies reversed the defect in efferocytosis, normalized the clearance of diseased vascular tissue, and ameliorated atherosclerosis in multi ple mouse models through the TNFα-driven programmed cell removal process 6 . Multiple advances were reported this year on the role of the gut microbiome in athero thrombosis. A link between gut microorganisms and atherosclerotic plaque development was first established in 2011, in which untargeted metabolomic and functional studies led to the discovery of the atherogenic metabolite trimethylamine N-oxide (TMAO) 7 . In a 2016 study of patients with stable CAD undergoing coronary angio graphy and plaque characterization, elevated plasma level of TMAO was shown to predict coronary athero sclerotic burden more powerfully than traditional cardiac risk factors 8 . Microbial production of TMAO was also reported to serve as a novel mech anism linking diet and specific gut microbiota with induction of heightened platelet responsiveness and enhanced thrombosis potential in vivo in both humans and other animals 9 . Initial clinical studies (n = 4,007) reported that plasma levels of TMAO independently predicted the risk of thrombotic events, and subsequent mechanistic studies showed that TMAO enhanced submaximal stimulusdependent platelet activation by multiple agonists through augmented Ca 2+ release from intracellular stores 9 . Complementary animalmodel studies employing dietary choline or TMAO, germ-free mice, and microbial transplantation collectively confirmed a role for gut microbiota and TMAO in modulating platelet hyper-responsiveness and thrombosis potential in vivo, and identified microbial taxa associated with plasma TMAO and thrombosis potential 9 . In another study, nonlethal inhibition of the rate-limiting microbial enzyme involved in generating TMAO from dietary choline was also shown to serve as a novel approach for the treatment of atherosclerosis 10 . These studies highlight the potential of targeting TMAO levels for the prevention and treatment of atherothrombosis.
In summary, numerous notable advances in atherosclerosis research were made in 2016. The power of genomics and other 'omics' technologies for discovery of new pathways linked to CAD development has begun to be realized, and has the potential to expand the number of therapeutic targets for atherosclerosis.
